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Objective: Maintenance therapy with anti-CD25 antibody has emerged as a potentially useful treatment for multiple sclerosis (MS). Constitutive CD25 expression on CD4 ϩ
CD25
ϩ regulatory T cells (T reg ) suggests that anti-CD25 antibody treatment may potentially target a subset of T cells that exhibit immune suppressive properties. We examined changes to CD4 ϩ
ϩ T reg in patients with MS receiving maintenance anti-CD25 monoclonal antibody treatment to determine the effect of treatment on T reg and, consequently, on immunological tolerance.
Design: Peripheral blood and cerebrospinal fluid samples obtained from a before-and-after trial of anti-CD25 antibody monotherapy were examined to compare baseline and treatment differences in CD4 ϩ CD25 ϩ T reg .
Subjects: A total of 15 subjects with MS. One subject was withdrawn owing to an adverse effect.
Results: Sustained reduction of the frequency of CD4 ϩ CD25 ϩ T reg was observed during treatment. Anti-CD25 antibody treatment led to evidence of impaired in vivo T reg proliferation and impaired ex vivo T reg suppression. Inflammatory MS activity was substantially reduced with treatment despite reduction of circulating T reg , and there was no correlation between changes in the frequency of T reg and changes in brain inflammatory activity. However, new-onset inflammatory disease, notably dermatitis, was also observed in a number of subjects during treatment.
Conclusion:
The reduction in T reg did not negatively affect maintenance of central nervous system tolerance during anti-CD25 antibody treatment. The incidence of newonset inflammatory disease outside of the central nervous system in a subset of patients, however, warrants further studies to examine the possibility of compartmental differences in the capacity to maintain tolerance in the setting of reduced CD4 ϩ CD25 ϩ T reg .
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T HE ANTI-CD25 MONOCLOnal antibody daclizumab targets the ␣ subunit of the high-affinity interleukin (IL)-2 cytokine receptor complex. The upregulation of CD25 following T cell activation and the subsequent IL-2 signaling constitutes a key event in T cell clonal expansion and differentiation. Abnormalities of the IL-2-CD25 cytokine pathway have been reported in a number of immune-mediated diseases including multiple sclerosis (MS) and suggest that CD25 is a potential target for MS immunotherapy. Increased soluble CD25 levels and abnormally high IL-2 responsiveness of autoreactive T cells in subjects with MS implicate an aberrant IL-2/ CD25 circuit in the pathogenesis of MS, and constitute the rationale for anti-CD25 antibody treatment to modulate IL-2 signaling in MS. 1, 2 A number of clinical studies are beginning to demonstrate the immunomodulatory effect of the anti-CD25 monoclonal antibody daclizumab in subjects with MS. 3, 4 Experimental evidence of the past decade has made increasingly clear that a subset of CD25-expressing CD4 ϩ T cells demonstrate suppressive or regulatory properties and contribute to the maintenance of immunological self-tolerance by their inhibitory influence on autoreactive T cells. 5 These CD4 ϩ CD25 ϩ regulatory T cells (T reg ) are distinguished from conventional activated T cells by constitutive high expression of CD25 and by the expression of T reg lineage specification factor forkhead box P3 (Foxp3). 6, 7 Conventional activated T cells, by contrast, express intermediate levels of CD25 and lack Foxp3. 6, 8 Whereas conventional activated T cells coordinate and amplify immune responses, CD4 ϩ CD25 ϩ T reg actively suppress immune responses, including those involved in autoimmunity. 9 The development of multiorgan inflammatory disease following T reg depletion indicates that CD4 ϩ CD25 ϩ T reg make a critical contribution to the maintenance of immunologic self-tolerance. 10 The loss or dysfunction of CD4 ϩ
CD25
ϩ T reg has been implicated in the pathogenesis of a growing number of disorders including systemic lupus erythematosus, 11 psoriasis, 12 aplastic anemia, 13 and MS, 14 suggesting a potentially broad relevance with respect to human autoimmune diseases.
The shared expression of CD25 on conventional activated T cells and CD4 ϩ
ϩ T reg suggest that both are potentially targeted by anti-CD25 antibody. Based on the knowledge that CD4 ϩ CD25 ϩ T reg contribute to maintenance of tolerance, an inhibitory effect on T reg could potentially exacerbate existing inflammatory disease or unmask underlying predilection for new inflammatory disease. We therefore examined the changes to the CD4 ϩ CD25 ϩ T cell subsets in subjects with MS undergoing anti-CD25 antibody treatment. In particular, we asked what effect an antihuman CD25 antibody has on CD4 ϩ CD25 ϩ T reg , whether changes to CD4 ϩ CD25 ϩ T reg affected the immunomodulatory effect of treatment, and whether changes to CD4 ϩ CD25 ϩ T reg affected maintenance of overall immunological tolerance.
METHODS

SAMPLES
Subjects with MS 15 were enrolled in an open-label trial of anti-CD25 antibody (daclizumab). Subjects were free of immunomodulatory therapy for 24 weeks prior to enrollment and received intravenous infusion of daclizumab monotherapy (1 mg/ kg) every 4 weeks for 54 weeks. Peripheral blood was obtained at baseline and during treatment. Cerebrospinal fluid was obtained at baseline and during treatment. Whole blood was processed immediately for fluorescence-activated cell sorting (FACS) analysis. Peripheral blood mononuclear cells (PBMC) available from 12 subjects were processed by Ficoll-Hypaque density centrifugation and cryopreserved for later use. All treatment samples were obtained just prior to administration of treatment (trough sample). Unless otherwise stated, baseline PBMC samples were compared with treated PBMC samples obtained at month 2.5 (trough sample following third dose). Brain magnetic resonance images were obtained monthly as previously described. 3 Informed consent was obtained from each subject. The study was reviewed and approved by the National Institute of Neurological Disorders and Stroke institutional review board.
FLOW CYTOMETRY
The following antibodies were used according to manufacturer's instructions: CD3, CD4, CD8, CD25 (M-A251), CD56, CD127, IL-2, Ki67, and pSTAT5 (signal transduction and activator of transcription 5) antibodies were obtained from BD Biosciences (San Jose, California). The Foxp3 phycoerythrin (PE) or allophycocyanin antibodies were obtained from eBioscience (San Diego, California). The CD25 (Anti-Tac) fluorescein isothiocyanate conjugate was from Immunotech (Westbrook, Maine). The CD25 (7G7) PE was from Ancell (Bayport, Minnesota). The FACS analysis of surface markers were performed on erythrocyte-lysed washed whole blood samples. The PBMC were used for all other analyses. Green Dead Stain (Invitrogen, Carlsbad, California) was used for live or dead cell discrimination with Foxp3 staining. Flow cytometric data was acquired on FACSCalibur (BD Biosciences) and analyzed on FlowJo (TreeStar, Ashland, Oregon).
T reg SUPPRESSION ASSAY
To compare T reg suppression between patients with MS at baseline and healthy donors, CD4 ϩ T cells were purified from PBMC by negative selection magnetic beads (Miltenyi, Auburn, California). Purity was more than 95%. The CD25-PE-labeled CD4 ϩ T cells were then sorted (FACS diva; BD Biosciences) into CD4 ϩ CD25 high T reg (highest, 3% CD25 expression) and CD4 ϩ CD25 − responder cells. The T reg coculture suppression assay was performed as previously described, 8 with minor modifications. Soluble anti-CD3 (HIT3a, 0.1µg/mL; BD Pharmingen, Franklin Lakes, New Jersy) was used for stimulation. Irradiated (3000 rad) T cell-depleted (MACS [magnetic activated cell sorting] cell separation/anti-CD3 microbeads; Miltenyi) autologous PBMC was used as accessory cells. Cells were plated in triplicate into 96-well plates, incubated at 37°C for 5 days, and pulsed with [ 
IMMUNOHISTOCHEMISTRY
Formalin-fixed paraffin-embedded tissue sections were prepared on poly-L-lysine coated slides. Immunohistochemistry for CD3 (Dako, Glostrup, Denmark) and Foxp3 (Abcam, Cambridge, Massachusetts) was carried out on consecutive tissue sections and developed with 3,3Ј-diaminobenzidine, tetrahydrochloride chromogen. A semiquantitative assessment of CD3 and Foxp3 expression was carried out by counting the number of positively stained lymphocytes under an objective microscopy lens at magnification ϫ40.
STATISTICAL ANALYSIS
Statistical significance was determined by unpaired t test to compare subjects with MS with healthy donors and by paired t test to compare baseline and treatment values. Where appropriate, comparisons were made using general linear model repeated measures analysis of variance. Pearson correlation coefficients were used to analyze relationships between parameters.
RESULTS
BASELINE CD4
؉ CD25
؉ T reg CHARACTERISTICS IN SUBJECTS WITH MS
To establish pretreatment characteristics of CD4 ϩ CD25 ϩ T reg in this cohort of subjects with MS, T reg suppression was measured by an in vitro T reg coculture assay 8 ( Figure 1A ). Most subjects in this cohort demonstrated baseline T reg suppression within the range for healthy donors (P=.27) ( Figure 1B) . Likewise, the frequency of circulating CD4
ϩ Foxp3 ϩ T reg in this cohort of subjects with MS did not differ significantly at baseline compared with that of age-, sex-, and race-matched healthy donors (P=.37) ( Figure 1C ). Furthermore, as in healthy donors, Foxp3 ϩ cells from subjects with MS were characterized by negative CD69 and low or negative CD127 expression 16, 17 and demonstrated attenuation of IL-2 production 6, 18 ( Figure 1D ).
REDUCTION OF FOXP3 ؉ REGULATORY T CELLS DURING ANTI-CD25 ANTIBODY TREATMENT
Antibody saturation was monitored during the course of anti-CD25 antibody treatment by flow cytometry using 2 fluorochrome-labeled antibodies (anti-Tac and 7G7) that bind noncompeting epitopes on CD25. Complete antibody saturation of CD25, demonstrated by the absence of fluorochrome-labeled anti-Tac binding, was maintained during the course of treatment (Figure 2A , antiTac), whereas reduction in the mean total CD25 expression on lymphocytes was less pronounced (13%) but nevertheless statistically significant (P Ͻ .001) (Figure 2A, 7G7) . Examination of cerebrospinal fluid demonstrated complete antibody saturation of CD25 on cerebrospinal fluid lymphocytes and a 20% decline in mean total CD25 expression during treatment (P =.04) ( Figure 2B ).
Signaling of IL-2 was inhibited by anti-CD25 antibody treatment. STAT5 phosphorylation, which mediates downstream IL-2 signaling, was used as a marker of IL-2 signaling. Lymphocytes obtained during treatment demonstrated nearly complete absence of STAT5 phosphorylation in response to low-level (10 U/mL) IL-2. Significant reductions in STAT5 phosphorylation were also observed at higher levels (50 and 100 U/mL) of IL-2 (P=.005) ( Figure 2C ).
The effect of anti-CD25 antibody treatment on CD4 ϩ CD25 ϩ T reg was analyzed by examining Foxp3 as a marker of T reg . Flow cytometric analysis ( Figure 2D ) demonstrated a reduction in mean fluorescence intensity of Foxp3 expression during treatment compared with baseline (PϽ .001) ( Figure 2E ). Reduction in Foxp3 expression at the single cell level during treatment is consistent with previous studies implicating STAT5 as a regulator of Foxp3 gene transcription. 19 Furthermore, the frequency of total Foxp3-expressing CD4 ϩ cells were reduced, with approximately 30% reduction in the mean frequency of CD4 ϩ Foxp3 ϩ cells observed by month 2.5 and 44% reduction by month 7.5 (PϽ.001) ( Figure 2F ). Similar reductions were observed in the frequency of CD4
ϩ cells (45% reduction; PϽ.001). Posttreatment samples available from a limited number of subjects demonstrated recovery of T reg frequencies to near baseline levels. 
REDUCTION OF T reg PROLIFERATIVE CAPACITY AND IMPAIRED T reg SUPPRESSION BY ANTI-CD25 ANTIBODY TREATMENT
Based on the known role of IL-2 in promoting cell cycle progression in conventional T cells, 20 we asked whether altered homeostatic proliferation of T reg could account for the reduction in frequency of T reg during treatment. The effect of anti-CD25 antibody treatment on T reg proliferation was examined using Ki67 expression to estimate the in vivo proliferating fraction, 21 determined as the proportion of CD4 ϩ
Foxp3
ϩ cells expressing Ki67. The PBMC from baseline and treatment were stained ex vivo for intracellular expression of Ki67. Consistent with a pre- (Figure 3A) , suggesting impaired homeostatic proliferation of T reg during anti-CD25 antibody treatment.
To assess T reg function, coculture suppression assays were performed to compare T reg suppression at baseline and during treatment. Because of altered CD25 expression during treatment, an additional surface marker, CD127, was used to sort T reg , which express low or no CD127 (CD127 low/neg ). 17 The FACS analysis demonstrated that most CD4 (Figure 3C and D) , indicating a functional impairment of ex vivo T reg suppression during anti-CD25 antibody treatment.
LACK OF CORRELATION BETWEEN REDUCTION OF T reg AND ACUTE CENTRAL NERVOUS SYSTEM INFLAMMATION
In addition to changes in T reg , anti-CD25 antibody treatment led to significant alteration in conventional activated CD4 ϩ CD25 ϩ T cells and CD56 bright natural killer (NK) cells. The frequency of conventional activated T cells (CD4 ϩ CD25 ϩ Foxp3 − ) was reduced during anti-CD25 antibody treatment (P Ͻ .001), which corresponded to the contraction of Ki67 ϩ proliferating fraction of conventional activated T cells. In contrast, the proportion of proliferating CD56
ϩ NK cells was increased during anti-CD25 antibody treatment and corresponded to the expansion of CD56 bright NK cells observed during the course of therapy (P Ͻ.001).
In the setting of simultaneous changes to activated conventional T cell and NK cell compartments, T reg were not necessarily the major determinants of acute central nervous system inflammation. Contrast (gadolinium dithylenetriamine pentaacetic acid [Gd-DTPA]) enhancement of MS lesions on brain magnetic resonance imaging, a marker of MS inflammatory activity, was assessed on a monthly basis. The number of MS lesions demonstrating Gd-DTPA enhancement (Gd-DTPA ϩ lesions) was significantly reduced during treatment with anti-CD25 antibody (P Ͻ .001) ( Figure 4A ). To assess whether the reduction in T reg had any negative effect on the immunomodulatory effect of anti-CD25 antibody, we analyzed the relationship between changes in the frequency of T reg and brain inflammatory activity. No significant correlations were observed between changes in the frequency of T reg and changes in brain inflammatory activity measured as the total number of Gd-DTPA ϩ lesions per month (r 2 =0.0171; P = .69) ( Figure 4B ) or the number of new Gd-DTPA ϩ lesions per month (r 2 = 0.0157; P=.71) when assessed at month 7.5. Analysis of earlier and later time points (months 2.5 and 12.5) yielded similar results (r 2 = 0.068 and r 2 = 0.0391, respectively, for correlation between change in total number of Gd-DTPA ϩ cells and T reg ).
NEW-ONSET INFLAMMATORY DERMATITIS AS AN ADVERSE EVENT DURING ANTI-CD25 ANTIBODY TREATMENT
Dermatitis occurred in 3 of 15 individuals who were taking anti-CD25 antibody (Table) . The onset of dermatitis occurred during anti-CD25 antibody treatment in 2 subjects and at the end of treatment in one subject who nevertheless still demonstrated more than 80% saturation of CD25 at the onset of dermatitis. An additional subject with a family history of rheumatoid arthritis developed palindromic rheumatism during treatment.
Reductions in the frequencies of Foxp3 ϩ cells for subjects who developed dermatitis are shown in the Table. Histologic examination of lesional skin from 2 subjects who developed dermatitis during treatment showed spongiotic to psoriasiform epidermal changes with perivascular lymphocytic inflammatory infiltrate in the subjacent superficial dermis ( Figure 4C and D) . In situ quantitative detection of Foxp3 in the lesional skin showed that approximately 13% of infiltrating CD3 ϩ cells were T reg ( Figure 4E and F) .
COMMENT
Here we demonstrate that long-term maintenance anti-CD25 antibody treatment led to sustained reduction of CD4 ϩ CD25 ϩ T reg in subjects with MS. In contrast to the hypoproliferative nature of T reg in culture, we and others 22 find evidence that T reg exhibit high replicative capacity in vivo. Reduced proliferating T reg fraction corresponds to decline in T reg numbers in the setting of impaired IL-2 signaling and suggests that IL-2-supported T reg proliferation accounts for a substantial portion of the human circulating T reg pool. Clinical trials in patients with cancer demonstrated upregulation of Foxp3 and increased frequency of T reg following administration of IL-2. 23, 24 Our data demonstrates, conversely, that negative perturbation of IL-2 signaling reduces Foxp3 expression and reduces the circulating T reg pool. Collectively, these studies indicate that IL-2 plays a major role in controlling the homeostatic set point for the size of the human circulating T reg pool.
We asked whether reduction in circulating T reg during anti-CD25 antibody treatment negatively affected MS inflammatory activity. Overall brain inflammatory activity was reduced during treatment, suggesting a shift toward tolerance. The lack of a correlation between changes in frequency of T reg and changes in brain inflammatory activity suggests that sustained reduction in circulating T reg did not negatively affect disease activity. One likely explanation is that simultaneous changes in other cell subsets during anti-CD25 antibody treatment countered any negative affect of reduced T reg . Anti-CD25 antibody treatment led to a contraction of the CD4 ϩ
CD25
ϩ activated conventional T cell fraction and an expansion of CD56 bright NK cells. A previous study demonstrated the capacity of CD56 bright NK cells to suppress inflammation; expansion of CD56 bright NK population is potentially a major determinant of acute brain inflammatory activity during anti-CD25 antibody treatment. 25 Alternatively, the lack of correlation between changes in circulating T reg and changes in brain inflammatory activity suggests the possibility that T reg are not a major determinant of acute inflammatory activity in MS. Data from experimental autoimmune encephalomyelitis, an animal model of MS, have not yet reconciled what role CD4 ϩ CD25 ϩ T reg play in modulating acute central nervous system inflammation. Loss of T reg appears to confer susceptibility to experimental autoimmune encephalomyelitis in an otherwise resistant strain of mice, 26 but central nervous system antigen-specific T reg failed to inhibit central nervous system effector T cells during the acute phase of experimental autoimmune encephalomyelitis, possibly owing to the in situ cytokine milieu, particularly IL-6, that renders effector T cells resistant to T reg suppression. Dermatitis occurred in 3 of the 15 subjects receiving treatment. An additional subject with a family history of rheumatoid arthritis developed migratory tenosynovitis during treatment, diagnosed as palindromic rheumatism. The incidence of new-onset inflammatory disease during anti-CD25 antibody treatment raised the possibility that there may be compartmental differences in the capacity to maintain tolerance in the setting of reduced circulating T reg . A recent study showed that CD4 ϩ CD25 ϩ T reg contribute to routine immune surveillance and inflammatory response in the human skin. 28 Furthermore, the availability of circulating T reg capable of mi- WWW.ARCHNEUROL.COM 477 grating into the skin was shown to be critical to the maintenance of skin-specific tolerance in an animal model, suggesting that the skin may be particularly vulnerable to reduction in circulating T reg . 29 Histologic findings from skin biopsies taken from our subjects were relatively nonspecific, but not inconsistent with what has been described in the Foxp3-deficiency syndrome immune dysregulation, polyendocrinopathy, enteropathy, X-linked (syndrome). 30 In situ quantitative detection of Foxp3 in the lesional skin showed that approximately 13% of infiltrating CD3 ϩ cells were T reg , which represents a lower frequency of T reg at the site of skin inflammation compared with historical controls. 31 Reduction in the frequency of T reg was relatively high (above the cohort mean/ median) in subjects who developed new-onset inflammatory disease, but did not reach statistical significance compared with those who did not develop new inflammatory disease on treatment. The relationship between reduction in T reg and new-onset inflammatory disease during anti-CD25 antibody treatment, though suggestive, is inconclusive, and further work is required to determine whether there are compartmental differences in requirements for CD4 ϩ
ϩ T reg to maintain organspecific tolerance.
A functional defect of CD4 ϩ CD25 ϩ T reg cells has been reported in subjects with MS. 14, 32 We found no significant difference in mean T reg suppression between our cohort of subjects with MS and healthy donors, suggesting either that a functional defect of T reg may not be a uniform finding in all subjects with MS or that the differences are on a scale that requires a larger cohort to adequately power such comparisons. Studies comparing T reg suppression in subjects with MS and healthy volunteers suggest that the differences may be age-dependent 33 or disease stage-dependent. 
